SEGMENTS

We currently manage our operations in two reportable segments, pharmaceuticals and diagnostics. The pharmaceuticals segment consists of two operating segments, our (i) pharmaceutical research and development segment which is focused on the research and development of pharmaceutical products, and vaccines, and (ii) the pharmaceutical operations we acquired in Chile, Mexico, Israel, Spain and Brazil. The diagnostics segment consists of two operating segments, our (i) pathology operations we acquired through the acquisition of OURLab and (ii) point-of-care and molecular diagnostics operations. There are no inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.

Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:



	For the three months ended September 30,						For the nine months ended September 30,
(In thousands)	2013			2012			2013			2012
Product revenues:
Pharmaceuticals	$	16,563		$	11,495		$	50,708		$	30,051
Diagnostics	—			—			—			—
Corporate	—			—			—			—
	$	16,563		$	11,495		$	50,708		$	30,051
Revenue from services:
Pharmaceuticals	$	—		$	—		$	—		$	—
Diagnostics	2,710			43			8,870			173
Corporate	60			57			180			159
	$	2,770		$	100		$	9,050		$	332
Revenue from transfer of intellectual property:
Pharmaceuticals	$	913		$	—		$	14,720		$	—
Diagnostics	395			200			1,360			400
Corporate	—			—			—			—
	$	1,308		$	200		$	16,080		$	400
Operating (loss) income:
Pharmaceuticals	$	(11,126	)	$	(1,755	)	$	(7,171	)	$	(5,072	)
Diagnostics	(399		)	(3,810		)	(16,783		)	(12,835		)
Corporate	(6,606		)	(3,804		)	(17,393		)	(9,650		)
Less: Operating loss attributable to noncontrolling interests	(879		)	—			(2,419		)	—
	$	(19,010	)	$	(9,369	)	$	(43,766	)	$	(27,557	)
Depreciation and amortization:
Pharmaceuticals	$	2,020		$	1,780		$	5,417		$	4,805
Diagnostics	1,717			841			5,110			2,510
Corporate	31			44			121			132
	$	3,768		$	2,665		$	10,648		$	7,447
Revenues:
United States	$	4,078		$	300		$	25,130		$	732
Chile	7,993			6,781			24,216			19,669
Spain	4,026			1,997			13,503			1,997
Israel	3,099			1,516			9,666			4,661
Mexico	1,445			1,201			3,323			3,724
	$	20,641		$	11,795		$	75,838		$	30,783



(In thousands)	September 30, 2013		December 31, 2012
Assets:
Pharmaceuticals	$	1,087,950	$	142,299
Diagnostics	114,434		112,422
Corporate	180,598		35,109
	$	1,382,982	$	289,830
Goodwill:
Pharmaceuticals	$	174,734	$	32,844
Diagnostics	47,606		47,606
Corporate	—		—
	$	222,340	$	80,450

During the three and nine months ended September 30, 2013 and 2012, no customer represented more than 10% of our total revenue. As of September 30, 2013 and December 31, 2012, no customer represented more than 10% of our accounts receivable balance.